{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:48:39Z","timestamp":1784591319899,"version":"3.55.0"},"reference-count":78,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA032080"],"award-info":[{"award-number":["R01DA032080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA032080"],"award-info":[{"award-number":["R01DA032080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA032080-05S1"],"award-info":[{"award-number":["R01DA032080-05S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA032080-05S1"],"award-info":[{"award-number":["R01DA032080-05S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K99\/R00DA043011"],"award-info":[{"award-number":["K99\/R00DA043011"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DP2DA053730"],"award-info":[{"award-number":["DP2DA053730"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-337-4656"],"award-info":[{"award-number":["IN-US-337-4656"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Hepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings who have undergone treatment provides the opportunity to gain insight into how to implement treatment programs that meet the needs of this population. Using Rhodes\u2019 Risk Environment Framework to guide our work, we conducted semi-structured interviews with 35 PWID who received HCV treatment in methadone clinics and drop-in-centers (DICs) in Nairobi and coastal Kenya supported by peer case managers from August to September 2019. Translated and transcribed interviews were analyzed thematically. Three overarching themes emerged in our thematic analysis: 1) Financial constraints as a barrier to HCV treatment, 2) HCV-related stigma, and 3) HCV treatment impacts on health and risk behaviors. These data signal unique challenges faced by PWID seeking HCV treatment in this LMIC setting and highlight the importance of interventions to reduce barriers to treatment. In order for positive treatment outcomes to be sustained, HCV treatment programs must address the barriers patients face at multiple levels and implement system-level changes.<\/jats:p>","DOI":"10.1371\/journal.pgph.0003284","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:29:38Z","timestamp":1737052178000},"page":"e0003284","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5613-0275","authenticated-orcid":true,"given":"Hannah N.","family":"Manley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-270X","authenticated-orcid":true,"given":"Lindsey R.","family":"Riback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Nyakowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cherutich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lizcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbe","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"pgph.0003284.ref001","author":"World Health Organization","year":"2023","journal-title":"Hepatitis C"},{"key":"pgph.0003284.ref002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13027-016-0071-z","article-title":"Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States","volume":"11","author":"ES Rosenthal","year":"2016","journal-title":"Infect Agent Cancer"},{"issue":"38","key":"pgph.0003284.ref003","doi-asserted-by":"crossref","first-page":"10811","DOI":"10.3748\/wjg.v21.i38.10811","article-title":"Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes","volume":"21","author":"S Ruta","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"12","key":"pgph.0003284.ref004","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"L Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"pgph.0003284.ref005","volume-title":"Key population size estimates in Kenya, 2020: Final report.","author":"National AIDS and STI Control Programme.","year":"2021"},{"key":"pgph.0003284.ref006","first-page":"19","article-title":"HIV and STI prevalence and injection behaviors among people who inject drugs in Nairobi: results from a 2011 bio-behavioral study using respondent-driven sampling","volume":"1","author":"W Tun","year":"2015","journal-title":"AIDS Behav"},{"issue":"12","key":"pgph.0003284.ref007","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","article-title":"Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030","volume":"2","author":"MW Sonderup","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"pgph.0003284.ref008","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(19)30264-6","article-title":"Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study","volume":"19","author":"MJ Akiyama","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pgph.0003284.ref009","article-title":"Global health sector strategy on viral hepatitis 2016\u20132021: Towards ending viral hepatitis.","author":"World Health Organization","year":"2016","journal-title":"2016 Contract No.: WHO\/HIV\/"},{"issue":"14","key":"pgph.0003284.ref010","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17144951","article-title":"Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.","volume":"17","author":"A Muller","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"pgph.0003284.ref011","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs.","volume":"51","author":"AK Asher","year":"2016","journal-title":"Subst Use Misuse."},{"issue":"3","key":"pgph.0003284.ref012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"pgph.0003284.ref013","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(18)30413-8","article-title":"Direct-acting antiviral therapy in sub-Saharan Africa","volume":"4","author":"CW Spearman","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"pgph.0003284.ref014","doi-asserted-by":"crossref","first-page":"ofy120","DOI":"10.1093\/ofid\/ofy120","article-title":"Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting.","volume":"5","author":"A Alimohammadi","year":"2018","journal-title":"Open Forum Infect Dis."},{"issue":"4","key":"pgph.0003284.ref015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis","volume":"72","author":"B Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"key":"pgph.0003284.ref016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.","volume":"10","author":"M Harris","year":"2013","journal-title":"Harm Reduct J"},{"issue":"9859","key":"pgph.0003284.ref017","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"R Lozano","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"pgph.0003284.ref018","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw121","article-title":"Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India.","volume":"3","author":"SH Mehta","year":"2016","journal-title":"Open Forum Infect Dis."},{"issue":"1","key":"pgph.0003284.ref019","doi-asserted-by":"crossref","first-page":"e0147879","DOI":"10.1371\/journal.pone.0147879","article-title":"Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India.","volume":"11","author":"SS Solomon","year":"2016","journal-title":"PLoS One."},{"issue":"1 Suppl","key":"pgph.0003284.ref020","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"H Midgard","year":"2016","journal-title":"J Hepatol"},{"key":"pgph.0003284.ref021","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","article-title":"High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic","volume":"47","author":"BL Norton","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"9","key":"pgph.0003284.ref022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy","volume":"165","author":"GJ Dore","year":"2016","journal-title":"Annals of internal medicine"},{"issue":"2","key":"pgph.0003284.ref023","doi-asserted-by":"crossref","first-page":"ofy001","DOI":"10.1093\/ofid\/ofy001","article-title":"Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.","volume":"5","author":"J Grebely","year":"2018","journal-title":"Open Forum Infectious Diseases."},{"issue":"5","key":"pgph.0003284.ref024","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"C Rossi","year":"2018","journal-title":"Journal of hepatology"},{"issue":"10","key":"pgph.0003284.ref025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.drugpo.2015.05.003","article-title":"Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.","volume":"26","author":"M Alavi","year":"2015","journal-title":"Int J Drug Policy."},{"issue":"3","key":"pgph.0003284.ref026","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2021.09.038","article-title":"Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs","volume":"76","author":"A Yeung","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"pgph.0003284.ref027","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","article-title":"Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.","volume":"25","author":"GJ MacArthur","year":"2014","journal-title":"Int J Drug Policy"},{"key":"pgph.0003284.ref028","article-title":"Exploring the Lived Experience of HCV Reinfection. International Network on Health and Hepatitis in Substance Users; Glasgow, Scotland","author":"AK McEwan","year":"2022"},{"issue":"3","key":"pgph.0003284.ref029","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users.","volume":"33","author":"SH Mehta","year":"2008","journal-title":"J Community Health"},{"issue":"10","key":"pgph.0003284.ref030","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/liv.14634","article-title":"Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era","volume":"40","author":"O Falade-Nwulia","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"pgph.0003284.ref031","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1080\/17441692.2021.1896763","article-title":"Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study.","volume":"17","author":"MJ Akiyama","year":"2022","journal-title":"Glob Public Health"},{"issue":"4","key":"pgph.0003284.ref032","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/QAI.0000000000000769","article-title":"HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya.","volume":"70","author":"AE Kurth","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pgph.0003284.ref033","article-title":"Gastroenterology Society of Kenya. Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya","author":"Government of Kenya","year":"2016"},{"issue":"8","key":"pgph.0003284.ref034","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jvh.13662","article-title":"Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya","volume":"29","author":"MJ Akiyama","year":"2022","journal-title":"J Viral Hepat"},{"key":"pgph.0003284.ref035","doi-asserted-by":"crossref","first-page":"103959","DOI":"10.1016\/j.drugpo.2023.103959","article-title":"Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.","volume":"113","author":"MJ Akiyama","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"5","key":"pgph.0003284.ref036","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1016\/S2214-109X(23)00057-8","article-title":"Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review","volume":"11","author":"L Degenhardt","year":"2023","journal-title":"The Lancet Global Health"},{"key":"pgph.0003284.ref037","volume-title":"Women who inject drugs and HIV: Addressing specific needs. Policy brief","author":"United Nations Office on Drugs and Crime","year":"2014"},{"issue":"3","key":"pgph.0003284.ref038","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.drugpo.2008.10.003","article-title":"Risk environments and drug harms: a social science for harm reduction approach","volume":"20","author":"T. Rhodes","year":"2009","journal-title":"Int J Drug Policy"},{"issue":"2","key":"pgph.0003284.ref039","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0955-3959(02)00007-5","article-title":"The \u2019risk environment\u2019: A framework for understanding and reducing drug-related harm","volume":"13","author":"T. Rhodes","year":"2002","journal-title":"International Journal of Drug Policy"},{"issue":"4","key":"pgph.0003284.ref040","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/10810730.2018.1448487","article-title":"Systematic Transcreation of Self-Help Smoking Cessation Materials for Hispanic\/Latino Smokers: Improving Cultural Relevance and Acceptability.","volume":"23","author":"B Pi\u00f1eiro","year":"2018","journal-title":"J Health Commun."},{"key":"pgph.0003284.ref041","author":"RE Boyatzis","year":"1998","journal-title":"Transforming qualitative information: Thematic analysis and code development: SAGE"},{"issue":"6","key":"pgph.0003284.ref042","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.","volume":"19","author":"A Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"1","key":"pgph.0003284.ref043","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12954-020-00409-9","article-title":"A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South","volume":"17","author":"JE Sherbuk","year":"2020","journal-title":"Harm Reduction Journal"},{"key":"pgph.0003284.ref044","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drugpo.2018.03.023","article-title":"Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.","volume":"57","author":"EU Patel","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"3","key":"pgph.0003284.ref045","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S2468-1253(16)30031-0","article-title":"Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments","volume":"1","author":"S Wait","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"pgph.0003284.ref046","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10461-013-0547-4","article-title":"A Review of the Role of Food Insecurity in Adherence to Care and Treatment Among Adult and Pediatric Populations Living with HIV and AIDS.","volume":"18","author":"S Young","year":"2014","journal-title":"AIDS and Behavior"},{"issue":"10","key":"pgph.0003284.ref047","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/QAD.0000000000001822","article-title":"Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression","volume":"32","author":"CC Almeida-Brasil","year":"2018","journal-title":"Aids"},{"issue":"5","key":"pgph.0003284.ref048","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10461-014-0730-2","article-title":"The Enabling Effect of Food Assistance in Improving Adherence and\/or Treatment Completion for Antiretroviral Therapy and Tuberculosis Treatment: A Literature Review.","volume":"18","author":"S de Pee","year":"2014","journal-title":"AIDS and Behavior"},{"issue":"5","key":"pgph.0003284.ref049","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s10461-014-0786-z","article-title":"Tailored Nutrition Education and Food Assistance Improve Adherence to HIV Antiretroviral Therapy: Evidence from Honduras.","volume":"18","author":"H Martinez","year":"2014","journal-title":"AIDS and Behavior"},{"issue":"1","key":"pgph.0003284.ref050","doi-asserted-by":"crossref","first-page":"e047205","DOI":"10.1136\/bmjopen-2020-047205","article-title":"Characteristics and impacts ofSystematic review nutritional programmes to address undernutrition of adults living with HIV in sub-Saharan Africa: a systematic review of evidence","volume":"12","author":"FH Tesfay","year":"2022","journal-title":"BMJ Open"},{"key":"pgph.0003284.ref051","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1186\/s12889-016-3671-z","article-title":"Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.","volume":"16","author":"ZC Rich","year":"2016","journal-title":"BMC Public Health."},{"key":"pgph.0003284.ref052","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/01.qai.0000248348.25630.74","article-title":"Antiretroviral Therapy in Resource-Poor Settings: Decreasing Barriers to Access and Promoting Adherence.","volume":"43","author":"JS Mukherjee","year":"2006","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"pgph.0003284.ref053","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.socscimed.2013.01.031","article-title":"Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting","volume":"83","author":"M Harris","year":"2013","journal-title":"Soc Sci Med"},{"issue":"4","key":"pgph.0003284.ref054","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/09540121.2016.1258451","article-title":"Impact of food, housing, and transportation insecurity on ART adherence: a hierarchical resources approach","volume":"29","author":"T Cornelius","year":"2017","journal-title":"AIDS Care"},{"key":"pgph.0003284.ref055","first-page":"265","article-title":"DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.","volume":"14","author":"B. Henry","year":"2018","journal-title":"J Health Biomed Law."},{"key":"pgph.0003284.ref056","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.drugpo.2017.03.013","article-title":"How economic recessions and unemployment affect illegal drug use: A systematic realist literature review","volume":"44","author":"GE Nagelhout","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"pgph.0003284.ref057","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.","volume":"75","author":"JL Butner","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"pgph.0003284.ref058","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.drugpo.2015.05.004","article-title":"Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.","volume":"26","author":"N Ford","year":"2015","journal-title":"Int J Drug Policy"},{"issue":"6","key":"pgph.0003284.ref059","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","article-title":"Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.","volume":"28","author":"M Hickman","year":"2015","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"pgph.0003284.ref060","doi-asserted-by":"crossref","first-page":"e0194162","DOI":"10.1371\/journal.pone.0194162","article-title":"The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.","volume":"13","author":"L Ti","year":"2018","journal-title":"PLoS One."},{"issue":"1","key":"pgph.0003284.ref061","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2019.09.022","article-title":"Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial","volume":"72","author":"SS Solomon","year":"2020","journal-title":"J Hepatol"},{"key":"pgph.0003284.ref062","doi-asserted-by":"crossref","first-page":"108587","DOI":"10.1016\/j.jsat.2021.108587","article-title":"Participation in methadone programs improves antiretroviral uptake and HIV viral suppression among people who inject drugs in Kenya.","volume":"134","author":"LW Mbogo","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"pgph.0003284.ref063","doi-asserted-by":"crossref","first-page":"103710","DOI":"10.1016\/j.drugpo.2022.103710","article-title":"Impact of COVID-19 on substance use disorder treatment services in Kenya: Qualitative findings from healthcare providers.","volume":"105","author":"A Muller","year":"2022","journal-title":"Int J Drug Policy."},{"key":"pgph.0003284.ref064","doi-asserted-by":"crossref","first-page":"102821","DOI":"10.1016\/j.drugpo.2020.102821","article-title":"Syringe services program (SSP) operational changes during the COVID-19 global outbreak.","volume":"83","author":"TS Bartholomew","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"7","key":"pgph.0003284.ref065","doi-asserted-by":"crossref","first-page":"e25583","DOI":"10.1002\/jia2.25583","article-title":"Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks","volume":"23","author":"TI Vasylyeva","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pgph.0003284.ref066","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12954-020-00432-w","article-title":"The impact of the COVID-19 pandemic on harm reduction services in Spain.","volume":"17","author":"CA Picchio","year":"2020","journal-title":"Harm Reduct J"},{"issue":"9","key":"pgph.0003284.ref067","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1007\/s10461-020-02886-2","article-title":"The Impact of COVID-19 on Syringe Services Programs in the United States","volume":"24","author":"SN Glick","year":"2020","journal-title":"AIDS Behav"},{"issue":"9","key":"pgph.0003284.ref068","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/1049732311405684","article-title":"Felt and enacted stigma among HIV\/HCV-coinfected adults: the impact of stigma layering.","volume":"21","author":"HM Lekas","year":"2011","journal-title":"Qual Health Res"},{"key":"pgph.0003284.ref069","doi-asserted-by":"crossref","first-page":"111013","DOI":"10.1016\/j.drugalcdep.2023.111013","article-title":"Shame and stigma in association with the HCV cascade to cure among people who inject drugs","volume":"253","author":"AW Batchelder","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"pgph.0003284.ref070","doi-asserted-by":"crossref","first-page":"103610","DOI":"10.1016\/j.drugpo.2022.103610","article-title":"\u2019Not just one box that you tick off\u2019\u2014Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective.","volume":"102","author":"AD Marshall","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"4\u20135","key":"pgph.0003284.ref071","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/1467-9566.13467","article-title":"Hepatitis C cure as a \u2018gathering\u2019: Attending to the social and material relations of hepatitis C treatment.","volume":"44","author":"A Farrugia","year":"2022","journal-title":"Sociology of Health & Illness."},{"issue":"9","key":"pgph.0003284.ref072","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial","volume":"170","author":"MJ Akiyama","year":"2019","journal-title":"Annals of internal medicine"},{"key":"pgph.0003284.ref073","doi-asserted-by":"crossref","first-page":"109878","DOI":"10.1016\/j.drugalcdep.2023.109878","article-title":"Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs","volume":"247","author":"JI Tsui","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"pgph.0003284.ref074","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/cid\/ciz633","article-title":"Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study","volume":"70","author":"AA Artenie","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pgph.0003284.ref075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.drugpo.2019.05.011","article-title":"Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review.","volume":"72","author":"M Caven","year":"2019","journal-title":"Int J Drug Policy."},{"key":"pgph.0003284.ref076","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.drugalcdep.2015.06.007","article-title":"\"Hepatitis C treatment turned me around:\" Psychological and behavioral transformation related to hepatitis C treatment.","volume":"153","author":"AW Batchelder","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"pgph.0003284.ref077","doi-asserted-by":"crossref","first-page":"208937","DOI":"10.1016\/j.josat.2022.208937","article-title":"The experience of re-infection among people who inject drugs successfully treated for hepatitis C.","volume":"146","author":"A Karasz","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"0 1","key":"pgph.0003284.ref078","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1097\/QAI.0000000000000659","article-title":"HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment.","volume":"2","author":"J Iversen","year":"2015","journal-title":"J Acquir Immune Defic Syndr."}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:29:59Z","timestamp":1737052199000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003284"}},"subtitle":[],"editor":[{"given":"Guillaume","family":"Fontaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0003284","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}